Fisher & Paykel Healthcare Corporation Limited (FSPKF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Fisher & Paykel Healthcare Corporation Limited (FSPKF) with AI Score 51/100 (Hold). Fisher & Paykel Healthcare Corporation Limited specializes in designing, manufacturing, and marketing medical device products and systems globally. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Fisher & Paykel Healthcare Corporation Limited (FSPKF) Healthcare & Pipeline Overview
Fisher & Paykel Healthcare Corporation Limited, established in 1934, is a global leader in medical devices for respiratory care and obstructive sleep apnea treatment. The company distinguishes itself through innovative humidification technology and a comprehensive product portfolio serving both acute and chronic care settings, with a significant presence in hospitals and home healthcare markets.
Investment Thesis
Fisher & Paykel Healthcare presents a compelling investment case based on its strong market position in respiratory care and OSA treatment. With a P/E ratio of 53.12 and a profit margin of 20.1%, the company demonstrates solid profitability. A key value driver is the increasing prevalence of respiratory diseases and sleep apnea, driving demand for its products. Growth catalysts include expanding its product offerings and penetrating new geographic markets. The company's beta of 0.93 suggests relatively low volatility compared to the market. However, potential risks include competition from other medical device manufacturers and regulatory changes in the healthcare industry. The dividend yield of 1.22% provides a modest income stream for investors.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $13.10 billion, reflecting its significant presence in the medical device industry.
- P/E ratio of 53.12, indicating investor expectations for future earnings growth.
- Profit margin of 20.1%, showcasing efficient operations and strong pricing power.
- Gross margin of 63.6%, highlighting the value-added nature of its products and services.
- Dividend yield of 1.22%, providing a steady income stream for shareholders.
Competitors & Peers
Strengths
- Strong market position in respiratory care and OSA treatment.
- Innovative humidification technology and product designs.
- Global distribution network and established brand reputation.
- High gross margin and profitability.
Weaknesses
- Reliance on specific product lines and market segments.
- Exposure to regulatory changes and healthcare policies.
- Potential for product recalls or safety concerns.
- Dependence on key suppliers and manufacturing facilities.
Catalysts
- Ongoing: Increasing prevalence of respiratory diseases and sleep apnea driving demand for respiratory care solutions.
- Ongoing: Expansion of the company's product portfolio and entry into new geographic markets.
- Upcoming: Potential regulatory approvals for new medical devices and therapies.
- Ongoing: Strategic partnerships and acquisitions to expand market reach and product offerings.
- Ongoing: Development and commercialization of digital health solutions for respiratory care.
Risks
- Potential: Competition from other medical device manufacturers and healthcare providers.
- Potential: Pricing pressures and reimbursement challenges in the healthcare industry.
- Potential: Regulatory changes and healthcare policy reforms.
- Potential: Product recalls or safety concerns related to medical devices.
- Ongoing: Economic downturns and healthcare budget constraints affecting demand for medical devices.
Growth Opportunities
- Expansion of Homecare Solutions: Fisher & Paykel Healthcare has a significant opportunity to expand its presence in the homecare market. With the increasing trend of patients receiving medical care at home, the demand for home-based respiratory care solutions is expected to rise. By developing and marketing innovative homecare products, such as CPAP devices and humidifiers, the company can tap into this growing market segment and increase its revenue. The global home healthcare market is projected to reach $360 billion by 2028, offering a substantial growth opportunity for Fisher & Paykel Healthcare.
- Penetration of Emerging Markets: Emerging markets, such as Asia-Pacific and Latin America, offer significant growth potential for Fisher & Paykel Healthcare. These regions have a large and growing population, increasing healthcare expenditure, and rising awareness of respiratory diseases and sleep apnea. By establishing a strong presence in these markets, the company can expand its customer base and increase its sales. This expansion could involve establishing local manufacturing facilities, partnerships with local distributors, and tailored product offerings to meet the specific needs of these markets. The emerging markets healthcare sector is expected to grow at a CAGR of 8-10% over the next five years.
- Development of New Respiratory Therapies: Fisher & Paykel Healthcare can drive growth by investing in the research and development of new respiratory therapies. By developing innovative products and solutions for respiratory diseases, such as asthma, COPD, and pneumonia, the company can address unmet medical needs and gain a competitive advantage. This could involve developing new drug delivery systems, advanced ventilation technologies, and personalized respiratory care solutions. The global respiratory therapy market is projected to reach $45 billion by 2027, presenting a significant opportunity for Fisher & Paykel Healthcare.
- Strategic Acquisitions and Partnerships: Fisher & Paykel Healthcare can accelerate its growth through strategic acquisitions and partnerships. By acquiring companies with complementary technologies or market access, the company can expand its product portfolio, enter new markets, and strengthen its competitive position. Partnerships with other healthcare providers, research institutions, and technology companies can also drive innovation and accelerate the development of new products and solutions. A well-executed acquisition strategy could add 5-10% to the company's revenue growth annually.
- Focus on Digital Health Solutions: Integrating digital health technologies into its respiratory care solutions presents a significant growth opportunity for Fisher & Paykel Healthcare. Developing connected devices, mobile apps, and data analytics platforms can enable remote patient monitoring, personalized therapy management, and improved patient outcomes. By leveraging digital health, the company can enhance its product offerings, improve patient engagement, and generate new revenue streams. The digital health market is expected to reach $660 billion by 2025, offering a substantial growth opportunity for Fisher & Paykel Healthcare.
Opportunities
- Expansion into emerging markets with growing healthcare needs.
- Development of new respiratory therapies and digital health solutions.
- Strategic acquisitions and partnerships to expand product portfolio.
- Increasing demand for home-based respiratory care solutions.
Threats
- Competition from other medical device manufacturers.
- Pricing pressures and reimbursement challenges.
- Patent expirations and generic competition.
- Economic downturns and healthcare budget constraints.
Competitive Advantages
- Strong brand reputation and established market presence in respiratory care.
- Proprietary humidification technology and innovative product designs.
- Extensive distribution network and global reach.
- High switching costs for customers due to product integration and training.
About FSPKF
Founded in 1934 and headquartered in Auckland, New Zealand, Fisher & Paykel Healthcare Corporation Limited has evolved into a prominent player in the medical device industry. The company designs, manufactures, and markets a wide range of products and systems focused on respiratory care and the treatment of obstructive sleep apnea (OSA). Its offerings cater to both acute and chronic respiratory conditions, addressing the needs of patients in hospitals and at home. Fisher & Paykel Healthcare's product portfolio includes humidification systems, nasal high flow therapy, noninvasive and invasive ventilation, infant respiratory care, masks, cannulas, and related accessories. Key products include the Airvo 2 humidified nasal high flow system, Optiflow nasal high flow therapy, and the F&P 850 System for ventilation. The company's products are used in various settings, including acute care, surgery, and home healthcare, providing solutions for respiratory support, resuscitation, and OSA treatment. Fisher & Paykel Healthcare distributes its products worldwide, maintaining a global presence and serving a diverse customer base of healthcare providers and patients.
What They Do
- Designs, manufactures, and markets medical device products and systems.
- Provides products for acute and chronic respiratory care.
- Offers solutions for the treatment of obstructive sleep apnea (OSA).
- Develops humidification systems for respiratory support.
- Produces nasal high flow therapy devices.
- Creates noninvasive and invasive ventilation systems.
- Provides infant respiratory care products, including resuscitation and CPAP therapy.
- Offers hospital and homecare products, including masks, cannulas, and accessories.
Business Model
- Designs and manufactures medical devices for respiratory care and OSA treatment.
- Sells products to hospitals, homecare providers, and patients worldwide.
- Generates revenue through product sales and related accessories.
- Invests in research and development to innovate new products and therapies.
Industry Context
Fisher & Paykel Healthcare operates within the medical instruments and supplies industry, a sector experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. The market is competitive, with key players focusing on innovation and expanding their product portfolios. Fisher & Paykel Healthcare distinguishes itself through its expertise in humidification technology and its focus on respiratory care and OSA treatment. The company competes with other medical device manufacturers, including ALBBY, ALBHF, BDUUY, CHEOF, and CHEOY, in a market characterized by stringent regulatory requirements and evolving healthcare practices.
Key Customers
- Hospitals and acute care facilities.
- Homecare providers and durable medical equipment suppliers.
- Patients with respiratory conditions and obstructive sleep apnea.
- Neonatal intensive care units (NICUs).
Financials
Chart & Info
Fisher & Paykel Healthcare Corporation Limited (FSPKF) stock price: Price data unavailable
Latest News
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FSPKF.
Price Targets
Wall Street price target analysis for FSPKF.
MoonshotScore
What does this score mean?
The MoonshotScore rates FSPKF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lewis G. Gradon
CEO
Lewis G. Gradon serves as the Chief Executive Officer of Fisher & Paykel Healthcare Corporation Limited. His career encompasses extensive experience within the healthcare and medical device sectors. Gradon has held various leadership positions within Fisher & Paykel Healthcare, contributing to the company's strategic direction and growth. His expertise spans product development, marketing, and global operations. Gradon's leadership is characterized by a focus on innovation, customer satisfaction, and operational excellence. He is responsible for managing a workforce of 6978 employees.
Track Record: Under Lewis G. Gradon's leadership, Fisher & Paykel Healthcare has achieved significant milestones, including expanding its global market share and launching innovative respiratory care solutions. He has overseen the company's growth in emerging markets and the development of new digital health technologies. Gradon has also focused on improving operational efficiency and strengthening the company's financial performance. His strategic decisions have contributed to Fisher & Paykel Healthcare's position as a leading player in the medical device industry.
FSPKF OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) markets, indicating that Fisher & Paykel Healthcare Corporation Limited (FSPKF) has not met the minimum qualifications for the OTCQX or OTCQB tiers. Companies in this tier may have limited financial disclosure, and there may be less information available to investors compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for limited liquidity, greater price volatility, and a lack of regulatory oversight compared to listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher price volatility compared to listed stocks.
- Risk of fraud or inadequate regulatory oversight.
- Limited access to company information and management.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and track record.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Monitor trading volume and price volatility.
- Understand the risks associated with OTC investing.
- Consult with a financial advisor before investing.
- Established history as Fisher & Paykel Healthcare Corporation Limited.
- Global presence and operations in the medical device industry.
- Focus on respiratory care and OSA treatment.
- Existing product portfolio and customer base.
- Management team with experience in the healthcare sector.
FSPKF Healthcare Stock FAQ
What does Fisher & Paykel Healthcare Corporation Limited do?
Fisher & Paykel Healthcare Corporation Limited is a global medical device company specializing in the design, manufacture, and marketing of products and systems for respiratory care and the treatment of obstructive sleep apnea (OSA). The company's offerings include humidification systems, nasal high flow therapy, noninvasive and invasive ventilation, and infant respiratory care products. These products are used in hospitals, homecare settings, and neonatal intensive care units (NICUs) to provide respiratory support, improve patient outcomes, and enhance the quality of life for individuals with respiratory conditions and OSA.
What do analysts say about FSPKF stock?
Analyst consensus on FSPKF stock is pending further AI analysis. Key valuation metrics include a P/E ratio of 53.12 and a dividend yield of 1.22%. Growth considerations include the increasing prevalence of respiratory diseases and OSA, the company's expansion into emerging markets, and the development of new respiratory therapies and digital health solutions. Investors should conduct their own research and consider their individual investment objectives and risk tolerance before making any investment decisions.
What are the main risks for FSPKF?
The main risks for Fisher & Paykel Healthcare Corporation Limited include competition from other medical device manufacturers, pricing pressures and reimbursement challenges in the healthcare industry, regulatory changes and healthcare policy reforms, potential product recalls or safety concerns, and economic downturns and healthcare budget constraints. Additionally, the company faces risks related to patent expirations, generic competition, and reliance on key suppliers and manufacturing facilities. Investors should carefully consider these risks before investing in FSPKF stock.
What are the key factors to evaluate for FSPKF?
Fisher & Paykel Healthcare Corporation Limited (FSPKF) currently holds an AI score of 51/100, indicating moderate score. Key strength: Strong market position in respiratory care and OSA treatment.. Primary risk to monitor: Potential: Competition from other medical device manufacturers and healthcare providers.. This is not financial advice.
How frequently does FSPKF data refresh on this page?
FSPKF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FSPKF's recent stock price performance?
Recent price movement in Fisher & Paykel Healthcare Corporation Limited (FSPKF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong market position in respiratory care and OSA treatment.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FSPKF overvalued or undervalued right now?
Determining whether Fisher & Paykel Healthcare Corporation Limited (FSPKF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FSPKF?
Before investing in Fisher & Paykel Healthcare Corporation Limited (FSPKF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for FSPKF stock.